NEW: APEC Research Portal
One of the key roles of APEC is to be the patient voice in world class research. We have launched a research portal so researchers who need APEC and patients to get involved can quickly ask for our support and provide us with all the information we need to quickly act to help.
The WILL Trial
The WILL trial aims to investigate the clinical effectiveness and cost-consequences of planned early term delivery at 38+0 to 38+3 weeks’ gestation, compared with expectant care at term until at least 40+0 weeks’ gestation, in pregnant women with chronic or gestational hypertension that develops by 37+6 weeks’ gestation.
PARROT-2 Follow on study assesses impact of PlGF tests
Researchers at Kings College London are in the process of conducting a follow on study to PARROT, PARROT-2. PlGF-based testing has been demonstrated to be useful in ruling out a diagnosis of pre-eclampsia.
The use of PLGF based tests in suspected pre-eclampsia
Placental growth factor (PlGF) is a protein involved in placental angiogenesis (the development of new blood vessels). In pre-eclampsia, levels of PlGF can be abnormally low.
Placental growth factor testing
Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.
Reducing maternal deaths from hypertensive disorders
Confidential inquiries into maternal deaths in the UK were established in 1952 and have aimed to report on every pregnancy related death since then.
The PHOENIX trial is a non-masked, randomised controlled trial, comparing planned early delivery with usual care in women with pre-eclampsia between 34+0 and 36+6 weeks’ gestation.
Latest research news
Cradle VSA Blood Pressure Monitor
Find out more about the world’s first medical device to detect shock and high blood pressure in pregnant women that could cut maternal deaths in developing countries by up to 25%, saving more than 70,000 lives a year.